Part 1 of this series covered the recovery and repair compounds most directly relevant to men over 40 training consistently — BPC-157, TB-500, GHK-Cu, and the foundation stack. This article goes deeper into a different but equally important category: longevity, cellular health, and the peptide framework that most men’s health content hasn’t caught up to yet.

The Khavinson peptides — developed over decades of research by Russian gerontologist Vladimir Khavinson and his team — represent a systematic approach to cellular aging that is genuinely different from the rest of the peptide landscape. Short di- and tri-peptides designed to regulate gene expression in aging tissues, restore organ function, and work at the population level as supplements rather than pharmaceutical interventions. The research base is substantial. The mainstream men’s health conversation has barely touched it.

This article also covers MOTS-C, a mitochondrial-derived peptide with compelling longevity, metabolic, and performance applications that bridges the cellular health focus of this article and the performance focus of Part 3.

A Reminder on How to Use This Information

The principles established in Part 1 apply fully here. Individual response to every compound in this article varies — N=1 always applies. Some men report clear and immediate effects. Others notice subtle changes over weeks or months. Others notice nothing from a particular compound, which may mean the dose needs adjusting, the delivery method isn’t right, or the compound simply isn’t the right fit for their individual physiology.

One week of a compound is not enough to evaluate it. Neither is one bottle. These are cellular-level interventions working on processes that don’t announce themselves. Evaluate over appropriate timeframes, track the right markers, and resist the urge to draw conclusions too early.

The Khavinson Framework: Cellular Aging at the Source

Vladimir Khavinson’s work begins with a straightforward observation: aging is largely a regulatory problem. Cells don’t lose the ability to function — they lose the signals that tell them to function correctly. Gene expression patterns shift with age. Tissues receive less precise instructions. Organ systems gradually decline not because the machinery is broken but because the signaling that coordinates it has degraded.

Khavinson’s solution was to develop short peptides — primarily di- and tri-peptides — that penetrate cell nuclei and interact directly with DNA to restore gene expression patterns toward a younger, more functional profile. Over more than 40 years of research including clinical trials with Russian Olympic athletes, cosmonauts, and aging populations, he developed more than 40 compounds designed to work as supplements at the population level rather than pharmaceutical interventions for disease.

The key distinction from most of the peptide landscape: these are not signaling molecules that tell the body to do something acutely. They are regulatory compounds that work over time to restore the precision of cellular communication that aging erodes. The timeframe for meaningful effects is longer. The applications are broader. And the risk profile, particularly for the oral compounds, is lower than most of the injectable peptides men are more familiar with.

Epitalon: Circadian Regulation and Cellular Longevity

Epitalon is a tetrapeptide developed from epithalamin, a natural extract of the pineal gland. It is one of the most studied compounds in the Khavinson library and one of the most directly relevant to men over 40 for several reasons.

Its primary mechanism involves telomerase activation — stimulating the enzyme that maintains telomere length, the protective caps on chromosomes that shorten with each cell division and are one of the most reliable biomarkers of biological aging. Epitalon has shown the ability to slow telomere shortening and in some studies to actually lengthen telomeres in aged cells. It also regulates the circadian rhythm through the pineal gland connection, which has downstream effects on melatonin production, sleep architecture, and the hormonal cascade that runs on circadian timing.

Reported effects in men who respond to it: improved sleep quality, more vivid and structured dreaming, better circadian rhythm regulation, and improved overall vitality and energy. It is worth noting that Epitalon is not primarily a sleep peptide — the sleep benefits are downstream effects of circadian regulation rather than the direct mechanism. Some men find it makes them more alert rather than sedated, particularly if timed incorrectly.

Oral bioavailability is meaningful through di- and tri-peptide transporters. Injectable administration may produce more palpable and faster effects for some individuals. Individual response varies significantly — one week of oral use may not be enough to draw conclusions either way.

Tier: Emerging with strong mechanistic data. Substantial long-term research from Khavinson’s group. Growing real-world validation.

Pinealon: Cognitive Function, Focus, and Mitochondrial Health

Pinealon is a tri-peptide — also from Khavinson’s research — with a distinctly different application profile from Epitalon despite sharing pineal gland origins. Its primary documented effects are cognitive: working memory improvement, focus and mental clarity, clean energy without the crash profile of stimulants, and mitochondrial modification in neurons.

The mitochondrial angle is particularly interesting. Pinealon appears to function as a mitochondrial modifier in neural tissue — improving the energy production efficiency of brain cells in ways that translate to better cognitive output. It has also shown effects on heart rate reduction during exercise and stimulant use, which has implications for both cardiovascular efficiency and stress response management.

Practical notes from real-world use: it tends to work better taken in the morning for a meaningful percentage of users, possibly due to genetic variation in peptide transporter expression. It synergizes well with stimulants including caffeine, and appears to have been part of the compound stack Khavinson developed for Russian Olympic athletes. Oral bioavailability is high through the same di- and tri-peptide transport system as Epitalon.

It has appeared in longevity research comparing it directly to compounds like rapamycin and berberine-resveratrol combinations — positioning it not just as a cognitive tool but as a genuine longevity molecule worth serious attention.

Tier: Emerging with strong mechanistic data. Khavinson research base solid. Less mainstream validation than Epitalon but growing.

Vilon and Thymogen: Immune Regulation and Aging

Two compounds from the Khavinson library worth including for men whose immune function is a priority — whether that means managing the immune decline that comes with age, recovering more effectively from illness, or supporting overall systemic resilience.

Vilon: A di-peptide designed for immune modulation at the population level. Works through thymus-related pathways to regulate immune response. Khavinson’s research positions it as a foundational longevity supplement — the kind of compound that doesn’t produce dramatic acute effects but supports the immune system’s long-term functional precision.

Thymogen: Another thymus peptide with more acute immune support applications. Particularly relevant in the context of infection — some practitioners use it alongside antibiotics during acute illness for synergistic immune response. For men who get hit hard when they get sick, or who notice immune resilience declining with age, Thymogen is worth investigating.

Both compounds represent the lower-risk end of the peptide spectrum — oral administration, well-established safety profiles from Khavinson’s research, and mechanisms that work with rather than override the body’s own regulatory systems.

Tier: Emerging with strong mechanistic data from Khavinson’s research program. Limited mainstream clinical data outside that body of work.

MOTS-C: The Mitochondrial Peptide Bridging Longevity and Performance

MOTS-C is in a category of its own — a peptide encoded not in nuclear DNA but in the mitochondrial genome, which gives it a unique mechanism and a broad application profile that spans longevity, metabolic health, and physical performance.

Its primary actions: improving insulin sensitivity and glucose metabolism, supporting mitochondrial biogenesis, reducing systemic inflammation, and enhancing exercise capacity. The metabolic effects are particularly meaningful — MOTS-C appears to activate AMPK pathways that regulate cellular energy homeostasis, producing effects that overlap meaningfully with caloric restriction and exercise at the cellular level. For men over 40 managing body composition alongside performance, those applications are directly relevant.

The longevity angle is compelling. MOTS-C levels decline with age and are associated with age-related metabolic decline. Restoring or supplementing those levels appears to partially reverse some of the metabolic aging that accumulates over decades. Research is still emerging but the mechanistic case is strong and real-world reports are consistently positive.

Performance applications are covered more fully in Part 3, where MOTS-C sits alongside other compounds targeting energy systems and exercise capacity. The cellular health and longevity mechanisms belong here. The distinction is worth understanding: MOTS-C works on the underlying biological machinery that performance depends on, not just the performance output itself. That’s a different and deeper application than most performance compounds offer.

Injectable administration is most common given the peptide’s size and the importance of bioavailability for the metabolic mechanisms. Individual response, as always, varies.

Tier: Emerging with strong mechanistic data. Growing research base. Real-world validation building.

Running These Compounds: Practical Principles

A few principles worth stating clearly for men considering compounds from this article:

Start with one compound at a time: The N=1 principle demands it. Adding multiple compounds simultaneously makes it impossible to attribute effects or non-effects to any specific one. Establish a baseline, add one compound, evaluate over an appropriate timeframe, then consider additions.

Timeframe matters more here than in Part 1: The Khavinson compounds in particular work on regulatory mechanisms that shift slowly. A week of Epitalon is not enough data. Neither is two weeks. Run these compounds for a minimum of four to six weeks before drawing conclusions about individual response.

Oral is a legitimate starting point: Several compounds in this article — Epitalon, Pinealon, Vilon, Thymogen — have meaningful oral bioavailability through di- and tri-peptide transporters. Injectable administration may produce stronger or faster effects for some individuals but oral is a practical and valid entry point.

Provider involvement matters: Particularly for MOTS-C and injectable protocols. A knowledgeable provider brings protocol design, sequencing knowledge, and the clinical experience to help interpret individual response meaningfully.

FROM THE FIELD

I’ve tried Epitalon and Pinealon — one week of oral use. Honest assessment: I didn’t notice much. No dramatic sleep improvement, no vivid dreams, no clear cognitive shift. One week is probably not enough to evaluate these compounds properly, and the oral dose and timing may not have been optimal for my individual response. I stopped, but I haven’t written them off.  Still have full bottles in the cabinet and will research them again. Nevertheless, the research is compelling and the people I know personally who run them consistently report real effects — meaningfully improved deep and REM sleep, vivid and structured dreaming, better morning energy. That’s consistent enough across credible sources to warrant a longer, better-structured trial.

My wife has been running MOTS-C for about four months — injectable. She’s serious about optimization and self-researched this one herself. What she’s noticed: metabolic improvements, better energy, improved body composition, and performance benefits that show up in her training. All of the above, not just one thing. That’s consistent with what the research suggests MOTS-C does when it’s working. It’s on my list.

Both experiences illustrate the N=1 principle in real time. One week of Epitalon with no noticeable effect doesn’t make it a bad compound — it makes it a compound I haven’t run long enough or optimally enough to evaluate for my own physiology. Someone else’s clear MOTS-C response doesn’t guarantee the same for you. The only way to know is to run it, monitor it, and give it an honest timeframe.

The Bottom Line

The Khavinson framework represents a serious and substantially researched approach to cellular aging that most men’s health content hasn’t caught up to. Epitalon and Pinealon in particular are worth understanding and considering for men whose priorities include cognitive performance, sleep quality, circadian regulation, and biological aging at the cellular level. Vilon and Thymogen for men focused on immune resilience. MOTS-C for the intersection of longevity and metabolic performance.

None of these are quick fixes. All of them require appropriate timeframes, honest individual evaluation, and the willingness to run a protocol without expecting to feel something dramatic in the first week. That discipline is what separates optimization from supplementation theater.

→ Part 1 of this series: Article 18 — Peptides Part 1: Recovery, Repair, and the Foundation Stack

→ Phase 3 overview: Article 16 — The Second Peak

→ Next: Article 20 — Peptides Part 3: Performance and Body Composition